Biosimilar ‘a’ flagging still a concern


Physicians should adopt a blanket process of refusing brand substitution until concerns regarding the PBAC’s ‘a’ flagging of biosimilars are addressed, says a senior gastroenterologist. Dr Greg Moore, chair of the Australian Inflammatory Bowel Disease Association (AIBDA) and Head of the Inflammatory Bowel Diseases, Gastroenterology and Hepatology Unit at Monash University, said he believed this ...


Already a member? Login to keep reading


OR
© 2017 the limbic